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Summary
 
We determined whether tumor cells consistently generating granulocyte/macrophage colony–
stimulating factor (GM-CSF) can recruit and activate macrophages to generate angiostatin and,
hence, inhibit the growth of distant metastasis. Two murine melanoma lines, B16-F10 (synge-
neic to C57BL/6 mice) and K-1735 (syngeneic to C3H/HeN mice), were engineered to pro-
duce GM-CSF. High GM-CSF (
 
.
 
1 ng/10
 
6
 
 cells)– and low GM-CSF (
 
,
 
10 pg/10
 
6
 
 cells)–pro-
ducing clones were identified. Parental, low, and high GM-CSF–producing cells were injected
subcutaneously into syngeneic and into nude mice. Parental and low-producing cells produced
rapidly growing tumors, whereas the high-producing cells produced slow-growing tumors.
Macrophage density inversely correlated with tumorigenicity and directly correlated with
steady state levels of macrophage metalloelastase (MME) mRNA. B16 and K-1735 subcutane-
ous (s.c.) tumors producing high levels of GM-CSF significantly suppressed lung metastasis of
3LL, UV-2237 fibrosarcoma, K-1735 M2, and B16-F10 cells, but parental or low-producing
tumors did not. The level of angiostatin in the serum directly correlated with the production of
GM-CSF by the s.c. tumors. Macrophages incubated with medium conditioned by GM-CSF–
producing B16 or K-1735 cells had higher MME activity and generated fourfold more an-
giostatin than control counterparts. These data provide direct evidence that GM-CSF released
from a primary tumor can upregulate angiostatin production and suppress growth of metastases.
Key words: angiogenesis • angiostatin • granulocyte/macrophage colony–stimulating factor • 
metastasis • tumor
 
T
 
he progressive growth and spread of neoplasms are de-
pendent on the formation of adequate vasculature, i.e.,
angiogenesis (1). The extent of angiogenesis depends on
the balance between positive and negative regulating mole-
cules released by both tumor cells and host cells, e.g., lym-
phoid cells (2–6). Angiogenesis begins with local degrada-
tion of the basement membrane of capillaries, followed by
invasion of the stroma by underlying endothelial cells in
the direction of an angiogenic stimulus. Subsequent to mi-
gration, endothelial cells proliferate at the leading edge of a
migrating column and then organize into three-dimen-
sional structures to form new capillary tubes (2–6). Inter-
ruption of any one of these steps can inhibit angiogenesis
(7) and thus metastasis.
Angiostatin is a specific inhibitor of endothelial cell pro-
liferation originally purified from the serum and urine of
mice bearing a murine Lewis lung carcinoma (3LL; refer-
ence 8). It is an internal fragment of plasminogen contain-
ing the first four triple loop disulfide-linked structures, with
an apparent molecule mass of 38 kD (8). Angiostatin iso-
lated from serum and urine of mice or from the proteolytic
degradation of human plasminogen is a potent inhibitor of
angiogenesis and, hence, of tumor growth in vivo (8, 9).
Proteolytic degradation of plasminogen by elastase (10),
urokinase plasminogen activator in PC3 human prostate
carcinoma cells (11, 12), human matrilysin, and human
gelatinase B (13) results in the production of angiostatin.
We have reported recently that the production of an-
giostatin by 3LL tumors growing subcutaneously (s.c. tu-
mors) is associated with the upregulation of murine metal-
loelastase (MME)
 
1
 
 in tumor-infiltrating macrophages (10).
Further, we concluded that MME induced by GM-CSF
can cleave plasminogen to angiostatin (10). Since MME
 
1
 
Abbreviations used in this paper: 
 
BCE, bovine capillary endothelial cell(s);
bFGF, basic fibroblast growth factor; FBS, fetal bovine serum; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; H, high (levels of GM-CSF–
producing); LBS-1, plasminogen lysine–binding site 1; L, low (levels of
GM-CSF–producing); MME, macrophage metalloelastase; PEM, perito-
neal exudate macrophage(s).
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expression in macrophages is upregulated by GM-CSF
(14), we wished to determine whether we could engineer
tumor cells to produce high levels of GM-CSF to recruit
macrophages and upregulate expression of MME, which
would lead to production of angiostatin and thus to inhibi-
tion of the outgrowth of cancer metastases.
 
Materials and Methods
 
Mice.
 
Athymic Ncr-nu/nu male mice were purchased from
the Animal Production Area, National Cancer Institute-Frederick
Cancer Research Facility (Frederick, MD). Specific pathogen–
free female C57BL/6 and C3H/HeN mice were purchased from
The Jackson Laboratory (Bar Harbor, ME). All mice were main-
tained under specific pathogen–free conditions in a facility ap-
proved by the American Association for Accreditation of Labora-
tory Animal Care. The care and experimental procedures were in
accordance with institutional guidelines and current regulations
and standards of the United States Department of Agriculture, the
Department of Health and Human Services, and the National Insti-
tutes of Health. The mice were used when they were 8–12 wk old.
 
Tumor Lines.
 
Metastatic murine Lewis lung carcinoma synge-
neic to C57BL/6 mice (3LL-met; obtained from Dr. M.
O’Reilly, Harvard Medical School, Boston, MA [8]), B16-F10
GM-CSF, a variant of the metastatic B16-F10 melanoma synge-
neic to C57BL/6 mice (15) transduced using an MFG retroviral
vector encoding murine GM-CSF (obtained from Dr. D. Pardoll,
Johns Hopkins University, Baltimore, MD), metastatic K-1735
M2 melanoma syngeneic to C3H/HeN mice (16), UV-2237M
fibrosarcoma syngeneic to C3H/HeN mice (17), and murine
RENCA renal carcinoma syngeneic to BALB/c mice (18) were
maintained as monolayer cultures in Eagle’s MEM supplemented
with sodium pyruvate, nonessential amino acids, 
 
l
 
-glutamine, vi-
tamin solution (GIBCO BRL, Gaithersburg, MD), and 5% (vol/
vol) heat-inactivated fetal bovine serum (FBS) at 10% CO
 
2
 
/95%
air at 37
 
8
 
C. The K-1735 M2 melanoma cells were transfected
with the plasmid pcDNA3-GM-CSF encoding for murine GM-
CSF driven by human cytomegalovirus promoter (a gift of Dr.
W. Yang, Academia Sinica, Taiwan) to derive K-1735 M2 GM-
CSF cells. K-1735 M2 cells transfected with pcDNA3 encoding
for neomycin resistance gene (K-1735 M2-Neo) served as a con-
trol. Cells resistant to 3 wk of continuous exposure to 800 
 
m
 
g/ml
G418 were selected.
B16-F10 GM-CSF and K-1735 M2 GM-CSF cells were sub-
cloned by limited dilution. Clones producing low (L) or high (H)
levels of GM-CSF were isolated as described below. Bovine capillary
endothelial cells (BCE; obtained from Dr. M. O’Reilly [8]) were
cultured on gelatinized plastic in DMEM/10% FBS supplemented
with 3 ng/ml human basic fibroblast growth factor (bFGF; Genzyme
Corp., Cambridge, MA). All cultures were free of mycoplasma and
the pathogenic murine viruses reovirus type 3, pneumonia virus of
mice, mouse adenovirus, murine hepatitis virus, lymphocyte chori-
omeningitis virus, ectromelia virus, and lactate dehydrogenase virus
(assayed by Program Resources, Inc., NCI-Frederick Cancer Re-
search and Development Center, Frederick, MD).
 
Measurement of GM-CSF Protein.
 
Tumor cells (10
 
5
 
) were
plated into 30-mm
 
2
 
 plates in medium containing 5% FBS. After
12 h, the cultures were washed with serum-free medium and
then cultured with 2 ml of medium containing 5% FBS for 24 h.
The level of GM-CSF in the culture supernatants was determined
using an ELISA kit according to the manufacturer’s instructions
(Quantikine; R&D Systems, Inc., Minneapolis, MN).
 
In Vivo Studies.
 
Cultures of wild-type and transfected tumor
cells in their exponential growth phase were harvested by a brief
trypsinization, washed in medium containing 10% FBS, and re-
suspended in HBSS. Different numbers of cells (0.5–4 
 
3
 
 10
 
5
 
 in
0.1 ml HBSS) were injected into the subcutis of the right flank of
syngeneic or nude mice. When tumors reached 8–10 mm in di-
ameter, unanesthetized syngeneic or nude mice were injected in-
travenously with 10
 
5
 
 K-1735 M2 melanoma cells or 10
 
5
 
 UV-
2273M cells. In another set of experiments, nude mice bearing
s.c. B16-F10 tumors were anesthetized with methoxyflurane.
The tumors in one group of mice were surgically excised, and the
area was closed with metal wound clips. The other group under-
went a sham surgical procedure. 1 d later, these mice were in-
jected intravenously with 10
 
5
 
 K-1735 M2 cells. The mice with
no s.c. tumors received intravenous injections of 3LL-met; K-1735
M2 cells served as additional controls. The mice were monitored
daily, killed 3 wk later, and necropsied. The lungs were weighed
and fixed in Bouin’s solution. The experimental lung metastases
were counted using a dissecting microscope.
To determine whether s.c. tumors that produce GM-CSF can in-
fluence the take and growth of tumor cells implanted at another sub-
cutaneous site, we injected B16-F10 GM-CSF cells from 8–10-mm
tumors into the subcutis on the right flank of nude mice. K-1735
M2 cells (10
 
5
 
) were injected into the subcutis of the contralateral
flank. Tumor size was determined twice weekly using a caliper.
Tumor volume was calculated by the formula, 
 
V
 
 
 
5
 
 (
 
A
 
 
 
3
 
 
 
B
 
2
 
)/2,
where 
 
V
 
 
 
5
 
 volume, 
 
A
 
 
 
5
 
 long diameter, and 
 
B
 
 
 
5
 
 short diameter.
 
Collection and Cultivation of Mouse Peritoneal Exudate Macrophages.
 
Peritoneal exudate macrophages (PEM) were collected by perito-
neal lavage with HBSS of mice injected intraperitoneally with 1.5
ml thioglycollate broth 4 d previously. The PEM were plated in
serum-free medium for 2 h on a 24-well dish at a density of 2 
 
3
 
10
 
5
 
 cells/well. 2 h later, nonadherent cells were removed. The
resultant adherent population was 98% pure according to immu-
nologic, morphologic, and phagocytic criteria (19).
 
Sample Preparations for Elastase and Angiostatin Assays.
 
To col-
lect tumor cell culture supernatants, tumor cells were plated at a
density of 2 
 
3
 
 10
 
6
 
/75 cm
 
2
 
, flasked, and cultured for 48 h in me-
dium containing 5% FBS. The culture supernatant fluids were
collected, centrifuged at 3,000 rpm for 10 min to remove intact
cells, aliquoted, and stored at 
 
2
 
80
 
8
 
C until use. For the elastase
and angiostatin assays, PEM were incubated for 24 h with tumor
cell culture supernatants diluted in medium containing 5% FBS.
The PEM were washed and incubated for another 72 h in 0.5
ml/well of serum-free DMEM/F12 medium in the absence or
presence of 100–200 
 
m
 
g/ml human plasminogen purified from
human plasma using a lysine–Sepharose 4B column (Pharmacia
Biotech AB, Uppsala, Sweden). The culture supernatants were
centrifuged at 3,000
 
 g
 
 for 30 min at 4
 
8
 
C. Elastase or angiostatin
activities were assessed as described below.
 
Elastase Assay.
 
Elastinolytic activity in macrophage-condi-
tioned medium was determined by a method described previ-
ously using [
 
3
 
H]NaBH
 
4
 
-labeled elastin as a substrate (20). In brief,
the samples were incubated for 16 h at 37
 
8
 
C with 600 
 
m
 
g of the
radiolabeled elastin in a reaction buffer (100 mM Tris-HCl, 5 mM
CaCl
 
2
 
, 0.2 mg/ml SDS, and 0.006% NaH
 
3
 
). Released (free-form)
 
3
 
H-peptide was harvested by centrifugation, and radioactivity was
monitored by scintillation counting. Enzyme activity was ex-
pressed as cpm per reaction.
 
Angiostatin Assay.
 
Angiostatin activity was assessed by inhibi-
tion of BCE proliferation as described previously (8). In brief,
BCE seeded at a density of 1.25 
 
3
 
 10
 
4
 
 cells/gelatinized well/0.5 ml
DMEM containing 10% FBS were allowed to adhere overnight, 
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then were rinsed and incubated for 20 min with 0.25 ml/well
DMEM/5% FBS or test samples. Additional medium containing
bFGF was added to a final concentration of 1 ng/ml. 72 h later, the
BCE were harvested by trypsinization and counted using a hemacy-
tometer. Angiostatin activity was determined from the formula for
inhibition of BCE proliferation and was expressed as a percentage.
 
Northern Blot Analysis.
 
Poly(A)
 
1
 
 mRNA was extracted from
10
 
7
 
 tumor cells at 70% confluence or from tumors growing in
vivo using the FastTrack mRNA isolation kit (Invitrogen Corp.,
San Diego, CA). mRNA was electrophoresed on a 1% denatur-
ing formaldehyde/agarose gel, electrotransferred at 0.6 A to Gene-
Screen nylon membrane (DuPont-NEN, Boston, MA), and UV
cross-linked with 120,000 
 
m
 
J/cm
 
2
 
 using a UV Stratalinker 1800
(Stratagene Inc., La Jolla, CA). Hybridization was performed as de-
scribed previously (21). The nylon filters were washed three times
at 55–60
 
8
 
C with 30 mM NaCl/3 mM sodium citrate (pH 7.2)/
0.1% SDS (wt/vol). The cDNA probes used in this analysis were
a 1.3-kb PstI cDNA fragment corresponding to rat glyceraldehyde
3-phosphate dehydrogenase (GAPDH; reference 22), a 1.7-kb
bamboo cDNA fragment of MME (provided by Dr. S.D. Shapiro,
Jewish Hospital at Washington University School of Medicine, St.
Louis, MO [23]), and a 1.0-kb PstI cDNA fragment of murine GM-
CSF. The cDNA fragments were radiolabeled using random primer
with 
 
a
 
-
 
32
 
P–labeled deoxyribonucleotide triphosphates (Amersham
Corp., Arlington Heights, IL). mRNA expression was quantified on
a laser densitometer (Ultrascan XL; LKB, Uppsala, Sweden). Each
sample measurement was calculated as the ratio of the average area of
the GM-CSF or MME to that of the GAPDH transcript and then
standardized using the smallest ratio in each group of samples.
 
Western Blot Analysis.
 
Samples
 
 
 
isolated from culture superna-
tants were mixed with sample buffer (62.5 mM Tris-HCl [pH
6.8], 2.3% SDS, 100 mM dithiothreitol, and 0.05% bromphenol
blue), boiled, and separated on 10% SDS-PAGE. The protein was
transferred onto 0.45-
 
m
 
m nitrocellulose membranes. The filter
was blocked with 3% BSA in Tris-buffered saline (20 mM Tris-
HCl [pH 7.5], 150 mM NaCl), probed with antibody against
plasminogen lysine-binding site (LBS)-1 (1 
 
m
 
g/ml) in Tris-buf-
fered saline containing 0.1% Tween 20, incubated with a second
antibody in the buffer, and visualized by the enhanced chemilu-
minescence Western blotting detection system (24).
 
Immunohistochemistry.
 
The presence of macrophages in tu-
mors was identified by immunohistochemistry using the mac-
rophage-specific scavenger receptor antibody (25). At necropsy,
tumors were cut into 5-mm
 
3
 
 pieces, placed in OCT compound
(Miles Inc., Elkhart, IN), and snap frozen in liquid nitrogen. Fro-
zen sections (8–10 
 
m
 
m) were air-dried, fixed with cold acetone,
rinsed with PBS, and treated with 3% hydrogen peroxide in
methanol (vol/vol). The treated slides were incubated in a block-
ing solution (5% normal human serum/1% normal goat serum in
PBS [vol/vol]) and then for 18 h with a rat polyclonal antibody
against scavenger receptor (Serotec Ltd., Kidlington, Oxford,
UK) at a 1:70 dilution at 4
 
8
 
C in a humidified chamber. The sec-
tions were then rinsed and incubated, first with the blocking so-
lution and then with a peroxidase-conjugated anti–rat antibody
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA)
at a 1:100 dilution. Positive reactions were visualized by incubat-
ing the slides for 1–5 min with Stable DAB (Research Genetics,
Huntsville, AL), followed by counterstaining with Mayer’s hema-
toxylin (Research Genetics). The slides were dried and mounted
with Universal mount (Research Genetics). Images were digi-
tized using a color video camera (3CCD; Sony Corp., Tokyo, Ja-
pan) and a personal computer equipped with image analysis soft-
ware (Optimas Corp., Bothell, WA).
 
Purification of Angiostatin from Murine Serum.
 
Mice were bled
from the lateral tail vein. Serum diluted 1:2 to 1:10 with PBS was
incubated overnight with lysine–Sepharose 4B (Pharmacia Bio-
tech AB) at 4
 
8
 
C. After washing with PBS and 0.3 M phosphate
buffer containing 3 mM EDTA (pH 7.4), lysine-binding proteins
were eluted with 0.2 M aminocaproic acid (pH 7.4). The ami-
nocaproic acid in the eluates was removed using a spin column
(Microcon 10; Amicon, Inc., Beverly, MA), and the proteins
were resuspended in 20 mM Tris-HCl (pH 7.6).
 
Statistical Analysis.
 
The significance of the in vitro data, lung
weight, and tumor volume was analyzed by the Student’s 
 
t
 
 test
(two-tailed). The difference in the number of lung metastases be-
tween groups was compared using the Mann-Whitney U test.
 
Results
 
Establishment of GM-CSF–producing Murine Melanoma Cell
Lines.
 
In the first set of experiments, we cloned GM-
CSF–transduced B16-F10 cells (20). Several clones produc-
ing 60–75 ng GM-CSF/10
 
6
 
 cells/24 h were combined, and
the line was designated B16-H (high). Three clones pro-
ducing 
 
,
 
10 pg GM-CSF/10
 
6
 
 cells/24 h were combined to
yield the B16-L (low) line. GM-CSF–transfected K-1735
M2 cells were also cloned (see Materials and Methods).
Several clones producing 1–2 ng GM-CSF/10
 
6
 
 cells/24 h
were combined to yield the K-1735-H line. Several clones
producing 
 
,
 
10 pg GM-CSF/10
 
6
 
 cells/24 h were com-
bined to yield the K-1735-L line. The level of GM-CSF
mRNA directly correlated with the level of protein (Fig. 1,
 
top 
 
and 
 
bottom
 
). Southern blot analysis indicated that re-
combinant GM-CSF DNA was intact in all the cell lines
(data not shown).
Figure 1. Northern blot analysis. Polyadenylated mRNA (2 mg/lane)
from cultured cells or tumors of B16-F10 (top) or K-1735 M2 (bottom)
was separated, blotted, and hybridized with cDNA fragments correspond-
ing to murine GM-CSF, MME, or rat GAPDH. P, Parental B16-F10 or
K-1735 M2; L, B16-L or K-1735-L; H, B16-H or K-1735-H. 
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The production of GM-CSF did not alter the in vitro
growth of the tumor cells. In contrast, tumorigenicity and
rate of growth of s.c. tumors (in syngeneic or nude mice)
inversely correlated with production of GM-CSF. B16-
F10 parental or B16-L cells produced 1,800-mm
 
3
 
 tumors
by day 25, whereas the B16-H tumors measured 321 mm
 
3
 
.
Similar results were obtained with the K-1735 melanoma.
3 wk after subcutaneous inoculation, K-1735 M2 parental,
K-1735-L, and K-1735-H cells produced 900-, 900-, and
310-mm
 
3
 
 tumors, respectively.
 
Macrophage Infiltration into s.c. Tumors and Expression of
MME.
 
Immunohistochemical staining of cryostat sections
using an mAb against the murine macrophage-specific scav-
enger receptor revealed that the density of tumor-infiltrat-
Figure 2. Macrophage infiltration into s.c. tumors. B16-F10 (top) or K-1735 M2 (bottom) tumors (8–10 mm in diameter) were resected, fixed in forma-
lin for hematoxylin and eosin staining (H&E) or in liquid nitrogen for immunohistochemical staining using antimacrophage-specific scavenger receptor
antibody (reference 42). 
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ing macrophages in B16-H (Fig. 2, 
 
top right
 
) and K-1735-H
(Fig. 2, 
 
bottom right
 
) tumors was threefold that in parental
(GM-CSF–negative) tumors. Specifically, the average
number of macrophages/100
 
3
 
 field in the B16-F10, B16-
L, and B16-H tumors was 23, 21, and 85, respectively. In
the K-1735 M2, K-1735-L, and K-1735-H s.c. tumors, the
average number of macrophages/100
 
3
 
 field was 11, 31,
and 65, respectively. Northern blot analysis indicated that
 
Table 1.
 
Suppression of Experimental Lung Metastasis by GM-CSF–producing s.c. Tumors
 
Tumors Challenge
Lung metastases
Lung weight Median Range
(
 
mg, mean 
 
6
 
 SD
 
)
Experiment 1 (C57BL/6 mice)
None, control 3LL-met 56 29–84 978 
 
6 146
B16-L 3LL-met 43 31–60 880 6 92
B16-H 3LL-met 17* 3–31 310‡ 6 57
Experiment 2 (C3H/HeN mice)
None, control UV-2237M 39 25–56 348 6 52
K-1735-L UV-2237M 27 14–36 325 6 39
K-1735-H UV-2237M 5* 0–13 237b 6 36
B16-L (5 3 104), B16-H (4 3 105), K-1735-L (105), or K-1735-H (105) cells were injected subcutaneously into C57BL/6 mice (n 5 10) or C3H/
HeN mice (n 5 5). When the s.c. tumors reached 8–10 mm in diameter, 105 3LL-met tumor cells or 2 3 105 UV-2237M cells were injected intra-
venously. Mice were killed 26 d later and necropsied. The lungs were weighed and fixed in Bouin’s solution, and the experimental lung metastases
(tumor colonies) were counted under a dissecting microscope.
*P ,0.01, compared with control (Mann-Whitney test).
‡P ,0.05, compared with control (Student’s t test, two-tailed).
Table 2. Nonimmunologic Suppression of Experimental Lung Metastasis by GM-CSF–producing B16 Melanoma Tumors Growing 
Subcutaneously in Nude Mice
Tumors Challenge Tumor
Lung metastases
Lung weight Median Range
(mg, mean 6 SD)
Experiment 1
None, control — K-1735 M2 164 148–289 1040 6 134
B16-L Sham surgery K-1735 M2 163 139–186 898 6 201
B16-L Resection K-1735 M2 171 146–201 1020 6 268
B16-H Sham surgery K-1735 M2 46* 26–61 322‡ 6 81
B16-H Resection K-1735 M2 185 173–214 967 6 268
Experiment 2
None, control — 3LL-met 53 21–84 995 6 198
B16-L Sham surgery 3LL-met 34 29–51 813 6 104
B16-L Resection 3LL-met 48 36–62 971 6 189
B16-H Sham surgery 3LL-met 16* 2–19 254‡ 6 43
B16-H Resection 3LL-met 50 33–63 877 6 140
Nude mice were injected subcutaneously with 5 3 104 B16-L or 4 3 105 B16-H cells. When the tumors reached 8–10 mm in diameter, the mice
were anesthetized and the tumors were resected from one group of mice (n 5 20), and the other group underwent sham surgery. 1 d later, the mice
were injected intravenously with 105 K-1735 M2 or 105 3LL-met cells. The mice were killed 3 wk later and necropsied. The lungs were weighed
and fixed in Bouin’s solution, and the experimental lung metastases (tumor colonies) were counted under a dissecting microscope.
*P ,0.01, compared with control (Mann-Whitney test).
‡P ,0.01, compared with control (Student’s t test, two-tailed).760 Regulation of Angiostatin Production by GM-CSF
number of lung metastases and their size (lung weight) pro-
duced by both 3LL-met and K-1735 M2 cells. In contrast,
the median number or size of lung metastases in mice
whose primary/s.c. tumor was resected did not differ from
control mice.
The B16-H tumors in the subcutis also suppressed the
growth of K-1735 M2 cells implanted into the contralateral
flank of nude mice (Fig. 3). By day 20 after inoculation of
the second tumor, the volume of the K-1735 M2 tumors
was 936 (132, 724 6 143, and 288 6 12 mm2 in mice
bearing a primary B16-P, B16-L, and B16-H s.c. tumor,
respectively; P ,0.01).
Angiostatin in the Serum of Tumor-bearing Mice. A previ-
ous report from our laboratory concluded that MME in-
duced by GM-CSF can cleave plasminogen to angiostatin
(10). To correlate the presence of angiostatin with suppres-
sion of metastases, we collected serum from normal mice
and mice with B16-L and B16-H s.c. tumors. The sera
were enriched for lysine-binding protein by passing through
a lysine–Sepharose 4B column, and the eluents were sepa-
rated on 10% SDS-PAGE, blotted, and probed with an
mAb against human LBS-1. Western blotting analysis dem-
onstrated that serum from both normal mice and mice
bearing B16-L tumors contained 38-kD protein(s) that re-
acted with the antibody (Fig. 4). The same band with sig-
nificantly higher intensity was found in the serum of mice
bearing B16-H tumors. These results suggest that angiosta-
tin is present in normal mice and that its production is up-
regulated in mice bearing B16-H but not B16-L tumors.
Generation of Angiostatin by Cultured Macrophages. PEM
were treated for 24 h with media conditioned by wild-type
or GM-CSF gene–engineered B16 or K-1735 cells. The
cells were then washed and incubated for an additional 72 h
in serum-free medium in the absence or presence of human
plasminogen. The resultant supernatants were assessed for
elastase (Fig. 5 A) and angiostatin (Fig. 5 B) activity. The
level of elastinolytic activity constitutively secreted by mouse
PEM was not altered by treatment with media conditioned
by B16-P, K-1735-P, B16-L, or K-1735-L cells. In con-
trast, PEM elastinolytic activity reached 1.5–2-fold the con-
trol levels with PEM incubated with media conditioned by
B16-H or K-1735-H (Fig. 5 A). Significantly higher an-
giostatin activity (determined by a bioassay using growth
inhibition of BCE) was found in supernatants of PEM with
higher MME activity and plasminogen. Specifically, the
mixture derived from control PEM or PEM conditioned
by medium of control tumor cells inhibited growth of
BCE by 10–15%, whereas the mixture from PEM incu-
Figure 3. Suppression of the growth of K-1735 M2 cells implanted
subcutaneously by distant s.c. B16-H tumors. Nude mice (n 5 10) were
injected subcutaneously with 4 3 105 B16-L (open squares) or 5 3 104
B16-H (filled circles) cells. When the tumors reached 8–10 mm in diame-
ter, K-1735 M2 cells (105/mouse) were injected subcutaneously into the
contralateral flank of tumor-bearing mice or normal mice (open circles)
serving as additional controls. Tumor size was measured twice weekly us-
ing a caliper, and tumor volume was calculated by the formula V 5 (A 3
B2)/2.
Figure 4. Identification of an-
giostatin in the serum. Angiosta-
tin in the serum of control or tu-
mor-bearing mice was purified
by a lysine–Sepharose 4B col-
umn, separated on 10% SDS-
PAGE, blotted, and identified
using an mAb against plasminogen LBS-1. N, Normal mice; L, mice
bearing B16-L tumors; H, mice bearing B16-H tumors.
tumors produced by B16-H and K-1735-H cells, but not
B16-L, K-1735-L, or their parental cells, expressed high
levels of GM-CSF and MME mRNA (Fig. 1, top and bot-
tom, in vivo). These results suggest that GM-CSF released
by tumor cells recruits macrophages and induces MME
gene expression in the tumor-infiltrating macrophages.
Suppression of Distant Tumor Growth by GM-CSF–producing
s.c. Tumors. We next determined whether the cells engi-
neered to produce GM-CSF could affect the growth of
distant tumors. Because we used tumors of different origins
for the local (s.c.) and secondary (metastases) challenges, we
could rule out the contribution of T cell–mediated specific
immune response in suppression of secondary tumors (26–
28). Specifically, B16-L and B16-H (syngeneic to C57BL/6
mice) or K-1735-L and K-1735-H cells (syngeneic to C3H
mice) were inoculated subcutaneously into syngeneic re-
cipients. When the tumors reached 8–10 mm in diameter,
3LL-met (syngeneic to C57BL/6 mice) or UV-2237M
(syngeneic to C3H mice) cells were injected intravenously
into the mice bearing B16 or K-1735 tumors, respectively.
In both tumor systems, the s.c. tumors produced by cells
releasing high amounts of GM-CSF (but not parental or
low GM-CSF–producing cells) significantly suppressed (P
,0.01) the growth of experimental lung metastasis by 3LL
or UV-2237M cells (Table 1).
Next, we injected B16-L or B16-H cells into the subcu-
tis of nude mice. When the tumors reached 10 mm in di-
ameter, the mice were anesthetized. One group (n 5 10)
underwent resection of the s.c. tumors, and the other (n 5
10) underwent sham surgery. 1 d later, the mice were in-
jected intravenously with 3LL-met K-1735 M2 cells. The
mice were killed 21 d later and necropsied, and the lung
metastases were counted under a microscope. The data
shown in Table 2 demonstrate that an intact s.c. B16-H
(but not B16-L) tumor significantly reduced the median761 Dong et al.
bated with medium conditioned by cells releasing high
amounts of GM-CSF inhibited BCE growth by 40–55%
(Fig. 5 B). The growth inhibition of BCE was neutralized
by treatment of the supernatants with antibodies against
LBS-1 but not by an isotype-matched control immunoglo-
bulin (Fig. 5 C). Western blot analysis using the antibody
to LBS-1 confirmed that the mixtures derived from PEM
treated by medium conditioned by B16-H or K-1735-H
cells contained significantly higher levels of the 38-kD pro-
tein (Fig. 5 D).
Discussion
The growth of metastases can accelerate subsequent to
resection of some primary neoplasms (29, 30). This acceler-
ated growth can be found in both autochthonous human
neoplasms and experimental rodent tumors, and is inde-
pendent of specific immune response (31–35). Sustained
tumor growth depends on an adequate supply of nutrients
and thus on angiogenesis (2, 36–38), which has led to ef-
forts to block the angiogenic pathway. Recent studies have
concluded that some primary neoplasms can induce the
production of a breakdown product from plasminogen
called angiostatin (8) that specifically inhibits proliferation
of vascular endothelial cells (8, 10). By thus inhibiting the
development of adequate vasculature, circulating angiosta-
tin can inhibit the growth of metastases and contribute to
dormancy of metastatic tumor cells (9, 12, 39–41). One
mechanism for the in vivo production of angiostatin in-
volves the upregulation of MME in macrophages that infil-
trate tumor cells that produce GM-CSF (10). Whether
GM-CSF–negative tumors engineered to produce GM-
CSF could thus generate production of angiostatin by infil-
trating macrophages remained unclear.
The present results demonstrate that s.c. tumors of B16
melanoma and K-1735 melanoma cells engineered to pro-
duce high amounts of GM-CSF were infiltrated by mac-
rophages, whereas parental (wild-type) or cells producing
low levels of GM-CSF were not. The production of GM-
CSF directly correlated with infiltrating macrophages’ MME
activity and production of circulating angiostatin and, hence,
growth inhibition of tumors implanted at a distant subcuta-
neous site or growing as lung metastases. In vitro analysis
indicated that treatment of macrophages with media condi-
tioned by cells producing a high level of GM-CSF in-
creased the secretion of MME and production of angiosta-
Figure 5. In vitro generation of MME
and angiostatin. Mouse PEM were treated
for 24 h in medium conditioned by B16-
F10 or K-1735 M2 cells. The cultures were
briefly rinsed and incubated for 72 h in se-
rum-free DMEM/F12 medium in the ab-
sence (a) or presence (b) of 100 mg/ml of
human plasminogen. MME activity (a) and
angiostatin activity (b) in the culture super-
natants were determined as described above.
Plasminogen fragments in the supernatants
were identified by Western blot analysis us-
ing an antibody against plasminogen LBS-1
(c). The angiostatin assay was conducted in
the presence of anti–LBS-1 (1, 5, or 10 mg/
ml) or control IgG (10 mg/ml) (d). M, Me-
dium; P, parental B16-F10 or K-1735 M2;
L, B16-L or K-1735-L; H, B16-H or
K-1735-H.762 Regulation of Angiostatin Production by GM-CSF
tin from plasminogen. These data confirmed our previous
findings (10, 14), and provide direct evidence that GM-
CSF can augment angiostatin production by upregulating
expression of MME in tumor-infiltrating macrophages.
Tumor cells producing a high level of GM-CSF had de-
creased tumorigenicity in both syngeneic and nude mice com-
pared with control cells or cells producing low levels of GM-
CSF. The reduced tumorigenicity was not restricted to that
produced by tumors injected in the subcutaneous site. B16
or K-1735 cells producing high levels of GM-CSF also had
a reduced incidence of experimental lung metastasis (data not
shown). The decrease in tumorigenicity could well be due
to tumor-infiltrating macrophages. First, the density of tu-
mor-infiltrating macrophages directly correlated with pro-
duction of GM-CSF. Second, preliminary analysis indicates
that tumor cells producing high levels of GM-CSF were
more susceptible to lysis mediated by macrophages than
low GM-CSF–producing counterparts (data not shown).
The production of GM-CSF by tumor cells has been
correlated with stimulation of antigen presenting cells and
induction of tumor-specific T cell–mediated immunity
(26–28). However, specific immunity cannot account for
the present results. We base this conclusion on results of
two major experiments. First, in many of the studies, s.c.
B16 tumors (producing GM-CSF) inhibited the outgrowth
of syngeneic but non–cross-reactive 3LL carcinoma cells.
Second, lung metastasis was inhibited in athymic nude
mice when GM-CSF–producing s.c. tumors were coin-
jected with metastatic allogeneic tumor cells.
In summary, we provide direct evidence that upregula-
tion of MME expression in macrophages by GM-CSF pro-
duced by local tumors can lead to generation of angiostatin
and, hence, growth suppression of distant metastases. Re-
cent data indicate that angiostatin can also be generated by
reduction and proteolysis of plasmin (11, 12) and by cleav-
age of plasminogen by gelatinase B and matrilysin (13). Re-
gardless of the biochemical mechanism, our data suggest
that chronic administration of GM-CSF or transduction of
the GM-CSF gene into tumor or normal tissue can be used
to treat cancer metastasis.
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